Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon

8 Jan 2025

Abstract excerpt

Introduction: The minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogs (NAs) can obtain hepatitis B surface antigen (HBsAg) clearance. Methods: In order to find out the advantaged population, we retrospectively collected 122 CHB patients treated with NAs alone or NAs plus PEG-IFN for 48 weeks, who were admitted to Sun Yat-sen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Hepatitis Viruses Studies and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39845839
DOI: 10.3389/fmed.2024.1510230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferonPMID 39845839Read ↗

Serological, molecular characteristics and cytokines profile of HBsAg negative/HBV DNA positive patients in clinicSemantic proximity Read ↗

Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.Semantic proximity Read ↗

The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment.Semantic proximity Read ↗

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.Semantic proximity Read ↗

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.Semantic proximity Read ↗

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.Semantic proximity Read ↗

Investigational RNA Interference Agents for Hepatitis BSemantic proximity Read ↗

Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.Semantic proximity Read ↗

New perspectives of biomarkers for the management of chronic hepatitis B.Semantic proximity Read ↗

Response predictors to treatment with pegylated interferon in chronic hepatitis B.Semantic proximity Read ↗

The Role of Prophylactic Antibiotics In Hepatitis B Virus-Related Acute-On-Chronic Liver Failure Patients: A Retrospective StudySemantic proximity Read ↗

Peginterferon α in the treatment of chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.